Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A

Inclusion Criteria: * Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial * Male subjects with the diagnosis of severe haemophilia A (FVIII\<1%) from age 18 years * Documented history of at least 150 exposure days to any other FVIII products (prevention or treatment of bleeds) * Immunocompetent (HIV (Human Immunodeficiency Virus) positive subjects should have CD4+ (Cluster of differentiation 4; a glycoprotein expressed on the surface) lymphocyte count \>200/microL) Exclusion Criteria: * Detectable inhibitors to FVIII (above or equal to 0.6 Bethesda Units (BU)) * History of FVIII inhibitors * Severe current hepatic dysfunction or severe hepatic disease during the last 12 months * Known or suspected allergy to trial product (FVIII) or related products * Subjects receiving immune modulating medication or immune tolerance induction (ITI) regimens * Body mass index (BMI) above 30 kg/m\^2